BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 25465598)

  • 1. Leptin replacement therapy for the treatment of non-HAART associated lipodystrophy syndromes: a meta-analysis into the effects of leptin on metabolic and hepatic endpoints.
    Rodríguez AJ; Neeman T; Giles AG; Mastronardi CA; Paz Filho G
    Arq Bras Endocrinol Metabol; 2014 Nov; 58(8):783-97. PubMed ID: 25465598
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Therapy resistant diabetes mellitus and lipodystrophy: leptin therapy leads to improvement].
    Jazet IM; Jonker JT; Wijngaarden MA; Lamb H; Smelt AH
    Ned Tijdschr Geneeskd; 2013; 157(4):A5482. PubMed ID: 23343738
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Leptin-replacement therapy for lipodystrophy.
    Oral EA; Simha V; Ruiz E; Andewelt A; Premkumar A; Snell P; Wagner AJ; DePaoli AM; Reitman ML; Taylor SI; Gorden P; Garg A
    N Engl J Med; 2002 Feb; 346(8):570-8. PubMed ID: 11856796
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Leptin decreases de novo lipogenesis in patients with lipodystrophy.
    Baykal AP; Parks EJ; Shamburek R; Syed-Abdul MM; Chacko S; Cochran E; Startzell M; Gharib AM; Ouwerkerk R; Abd-Elmoniem KZ; Walter PJ; Walter M; Muniyappa R; Chung ST; Brown RJ
    JCI Insight; 2020 Jul; 5(14):. PubMed ID: 32573497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Leptin reverses insulin resistance and hepatic steatosis in patients with severe lipodystrophy.
    Petersen KF; Oral EA; Dufour S; Befroy D; Ariyan C; Yu C; Cline GW; DePaoli AM; Taylor SI; Gorden P; Shulman GI
    J Clin Invest; 2002 May; 109(10):1345-50. PubMed ID: 12021250
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term efficacy of leptin replacement in patients with generalized lipodystrophy.
    Javor ED; Cochran EK; Musso C; Young JR; Depaoli AM; Gorden P
    Diabetes; 2005 Jul; 54(7):1994-2002. PubMed ID: 15983199
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Leptin reverses nonalcoholic steatohepatitis in patients with severe lipodystrophy.
    Javor ED; Ghany MG; Cochran EK; Oral EA; DePaoli AM; Premkumar A; Kleiner DE; Gorden P
    Hepatology; 2005 Apr; 41(4):753-60. PubMed ID: 15791619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of efficacy and safety of leptin replacement therapy in moderately and severely hypoleptinemic patients with familial partial lipodystrophy of the Dunnigan variety.
    Simha V; Subramanyam L; Szczepaniak L; Quittner C; Adams-Huet B; Snell P; Garg A
    J Clin Endocrinol Metab; 2012 Mar; 97(3):785-92. PubMed ID: 22170723
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effects of recombinant human leptin on visceral fat, dyslipidemia, and insulin resistance in patients with human immunodeficiency virus-associated lipoatrophy and hypoleptinemia.
    Mulligan K; Khatami H; Schwarz JM; Sakkas GK; DePaoli AM; Tai VW; Wen MJ; Lee GA; Grunfeld C; Schambelan M
    J Clin Endocrinol Metab; 2009 Apr; 94(4):1137-44. PubMed ID: 19174500
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy.
    Park JY; Chong AY; Cochran EK; Kleiner DE; Haller MJ; Schatz DA; Gorden P
    J Clin Endocrinol Metab; 2008 Jan; 93(1):26-31. PubMed ID: 17940115
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Consequences of stopping and restarting leptin in an adolescent with lipodystrophy.
    Kamran F; Rother KI; Cochran E; Safar Zadeh E; Gorden P; Brown RJ
    Horm Res Paediatr; 2012; 78(5-6):320-5. PubMed ID: 22965160
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Leptin activates hepatic 5'-AMP-activated protein kinase through sympathetic nervous system and α1-adrenergic receptor: a potential mechanism for improvement of fatty liver in lipodystrophy by leptin.
    Miyamoto L; Ebihara K; Kusakabe T; Aotani D; Yamamoto-Kataoka S; Sakai T; Aizawa-Abe M; Yamamoto Y; Fujikura J; Hayashi T; Hosoda K; Nakao K
    J Biol Chem; 2012 Nov; 287(48):40441-7. PubMed ID: 23024365
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The liver diseases of lipodystrophy: the long-term effect of leptin treatment.
    Safar Zadeh E; Lungu AO; Cochran EK; Brown RJ; Ghany MG; Heller T; Kleiner DE; Gorden P
    J Hepatol; 2013 Jul; 59(1):131-7. PubMed ID: 23439261
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of Metreleptin in Pediatric Patients With Lipodystrophy.
    Brown RJ; Meehan CA; Cochran E; Rother KI; Kleiner DE; Walter M; Gorden P
    J Clin Endocrinol Metab; 2017 May; 102(5):1511-1519. PubMed ID: 28324110
    [TBL] [Abstract][Full Text] [Related]  

  • 15. One-year metreleptin improves insulin secretion in patients with diabetes linked to genetic lipodystrophic syndromes.
    Vatier C; Fetita S; Boudou P; Tchankou C; Deville L; Riveline J; Young J; Mathivon L; Travert F; Morin D; Cahen J; Lascols O; Andreelli F; Reznik Y; Mongeois E; Madelaine I; Vantyghem M; Gautier J; Vigouroux C
    Diabetes Obes Metab; 2016 Jul; 18(7):693-7. PubMed ID: 26584826
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant methionyl human leptin therapy in replacement doses improves insulin resistance and metabolic profile in patients with lipoatrophy and metabolic syndrome induced by the highly active antiretroviral therapy.
    Lee JH; Chan JL; Sourlas E; Raptopoulos V; Mantzoros CS
    J Clin Endocrinol Metab; 2006 Jul; 91(7):2605-11. PubMed ID: 16636130
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of leptin-replacement therapy and possible mechanisms of leptin actions in patients with generalized lipodystrophy.
    Ebihara K; Kusakabe T; Hirata M; Masuzaki H; Miyanaga F; Kobayashi N; Tanaka T; Chusho H; Miyazawa T; Hayashi T; Hosoda K; Ogawa Y; DePaoli AM; Fukushima M; Nakao K
    J Clin Endocrinol Metab; 2007 Feb; 92(2):532-41. PubMed ID: 17118991
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Treatment of diet-induced lipodystrophic C57BL/6J mice with long-acting PASylated leptin normalises insulin sensitivity and hepatic steatosis by promoting lipid utilisation.
    Bolze F; Bast A; Mocek S; Morath V; Yuan D; Rink N; Schlapschy M; Zimmermann A; Heikenwalder M; Skerra A; Klingenspor M
    Diabetologia; 2016 Sep; 59(9):2005-12. PubMed ID: 27272237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The clinical efficacy of the adipocyte-derived hormone leptin in metabolic dysfunction.
    Gorden P; Park JY
    Arch Physiol Biochem; 2006 Apr; 112(2):114-8. PubMed ID: 16931453
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effects of leptin replacement therapy on pancreatic β-cell function in patients with lipodystrophy.
    Muniyappa R; Brown RJ; Mari A; Joseph J; Warren MA; Cochran EK; Skarulis MC; Gorden P
    Diabetes Care; 2014 Apr; 37(4):1101-7. PubMed ID: 24496806
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.